Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Source: Senate LDA
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Combination Drug Development Incentive Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
MODDERN Cures Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Drug Quality and Security Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390)
Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369
Average Sales Price; Reimbursement; Children Health Insurance Program Act of 2015; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation); TPA, TTP.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation); TPA, TTP.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; 21st Century Cures Proposal.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
n/a
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed Changes Being Effected Labeling Rule; 21st Century Cures Proposal.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation); TPA, TTP.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation)
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implmentation]; Food and Drug Administration Proposed CBE Labeling Rule; 21st Century Cures Proposal
HR 5771 Tax Increase Prevention Act of 2014
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed CBE Labeling Rule
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain", Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation)
Illegal Compounding of Animal Drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain"; Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Transatlantic Trade & Investment Partnership (TTIP) - Proposed Free Trade Agreement between the European Union and the United States. (Market Access; Industry-Specific Regulation; Broader Rules and Principles and Modes of Co-operation)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importationi; Non Interference
Healthcare Exchanges; Protected Classes; CMS Rule
Illegal Compounding of Animal Drugs
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Healthcare Exchanges; Protected Classes
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain (H.R. 2775)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Shortages; Supply Chain Security; Risk Evaluatioin and Mitigation Strategies (REMS); Compounding
Patent Settlements
Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs); Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security; Patent Settlements
Illegal Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff; Importation; Non Interference; Supply Chain Security; Patent Settlements
Patent Settlements
Illegal Compounding
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Patent Settlements
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D
Patent Settlements
Illegal Compounding
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Patent Settlements; H.R. 1706 and S. 5369
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D/Debt Ceiling
Illegal Compounding of Animal Drugs
Food and Drug Administration Safety & Innovation Act (FDASIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Transatlantic Trade & Investment Partnership (TTIP)
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Food and Drug Administration Safety & Innovationi Act (FDASIA) - Updates/Implementation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Patent Settlements; Patent Trolls (H.R. 3390)
Transatlantic Trade & Investment Partnership (TTIP)
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Illegal Compounding
Patent Settlements
Transatlantic Trade & Investment Partnership (TTIP)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Illegal Compounding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Gain Act; Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Settlements
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Illegal Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Drug Shortages; The Preserving Access to Life Savings Medicines Act (s. 296)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE